Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
HMGB1 as a Key Driver of B Cell Hyperactivity in the Pathogenesis of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
FY 2021-22
Summary
Pulmonary Hypertension (PH) is a progressively fatal disease defined by a resting mean pulmonary arterial pressure of 20 mmHg. A subset of PH, known as pulmonary arterial hypertension (PAH) is localized to the lung vasculature and is characterized by perivascular inflammation and pulmonary arterial remodelling. This aggressive subset of PH is often associated with connective tissue diseases such as systemic sclerosis (SSc) and is the leading cause of death in these patients, with a 4-year mortality rate of 50%. Current therapies for systemic sclerosis associated PAH (SSc-PAH) are limited to vasodilators and are largely unsuccessful. Due to the immunological nature of both diseases, accumulating evidence points to immunomodulation as the future of SSc-PAH treatment.
Given the central role of the immune system in the pathogenesis of both SSc and PAH, my project seeks to further investigate the role of B cells and the inflammatory modulator, high mobility group box 1 (HMGB1), in the pathogenesis of SSc-PAH. Recent research by our lab has shown that HMGB1 drives immune cell activation and promotes the release of pro-inflammatory cytokines (IL-6, TNF-a, IL-1B) driving perivascular inflammation and B cell activation.My project will investigate the relationship between HMGB1 and B cell hyperactivity. I hypothesize that extracellular matrix dysfunction in SSc promotes the release of HMGB1, which in turn stimulates B cell activity via TLR4 signaling, resulting in the onset of PAH in SSc. If successful, this project will help implicate B cells as key drivers of autoimmunity and vascular inflammation in SSc-PAH. This work will deepen our understanding of the disease mechanisms and provide new therapeutic targets (B cells, HMGB1) in the treatment of this devastating disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466768
Name
Sulstarova Sonja
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
HMGB1 as a Key Driver of B Cell Hyperactivity in the Pathogenesis of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmunity; B Cell Hyperactivity; Hmgb1; Lung Physiology; Perivascular Inflammation; Pulmonary Arterial Hypertension; Systemic Sclerosis
Abstract
Pulmonary Hypertension (PH) is a progressively fatal disease defined by a resting mean pulmonary arterial pressure of 20 mmHg. A subset of PH, known as pulmonary arterial hypertension (PAH) is localized to the lung vasculature and is characterized by perivascular inflammation and pulmonary arterial remodelling. This aggressive subset of PH is often associated with connective tissue diseases such as systemic sclerosis (SSc) and is the leading cause of death in these patients, with a 4-year mortality rate of 50%. Current therapies for systemic sclerosis associated PAH (SSc-PAH) are limited to vasodilators and are largely unsuccessful. Due to the immunological nature of both diseases, accumulating evidence points to immunomodulation as the future of SSc-PAH treatment.
Given the central role of the immune system in the pathogenesis of both SSc and PAH, my project seeks to further investigate the role of B cells and the inflammatory modulator, high mobility group box 1 (HMGB1), in the pathogenesis of SSc-PAH. Recent research by our lab has shown that HMGB1 drives immune cell activation and promotes the release of pro-inflammatory cytokines (IL-6, TNF-a, IL-1B) driving perivascular inflammation and B cell activation.My project will investigate the relationship between HMGB1 and B cell hyperactivity. I hypothesize that extracellular matrix dysfunction in SSc promotes the release of HMGB1, which in turn stimulates B cell activity via TLR4 signaling, resulting in the onset of PAH in SSc. If successful, this project will help implicate B cells as key drivers of autoimmunity and vascular inflammation in SSc-PAH. This work will deepen our understanding of the disease mechanisms and provide new therapeutic targets (B cells, HMGB1) in the treatment of this devastating disease.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sulstarova, Sonja
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~